Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)

Use of the recently FDA-approved PDGFR alpha monoclonal antibody olaratumab in combination with doxorubicin as front-line therapy for advanced STS
3:27 minutes.

Classification, incidence and management of sarcomas

Integration of the recently FDA-approved agents trabectedin and eribulin into the treatment algorithms for metastatic liposarcoma and leiomyosarcoma

Recent FDA approval of olaratumab in combination with doxorubicin and integration into the treatment algorithm for advanced STS

Role of tyrosine kinase inhibitors and immune checkpoint inhibitors in STS